PREOPERATIVNA PRIPREMA BOLESNIKA NA HRONIČNOJ ANTITROMBOTIČKOJ TERAPIJI ZA ELEKTIVNU NESRČANU HIRURGIJU
English
Sažetak
Preoperativna priprema bolesnika na antitrombotičkoj terapiji (antiagregaciona i antikoagulantna terapija) izazovna je, zbog toga što prekid terapije nosi rizik od tromboembolijskog događaja, a operacija je povezana sa rizikom od krvarenja. Mora se napraviti balans između tromboembolijskog rizika i rizika od krvarenja i doneti odluka o tome da li će antitrombotička terapija biti prekinuta. Svaki bolesnik zahteva individualan pristup. Ovo znači izračunavanje tromboembolijskog rizika i rizika od krvarenja za svakog bolesnika. Rizik od krvarenja je zasnovan na individualnim karakteristikama bolesnika i riziku koji nosi sama hirurška intervencija. Tromboembolijski rizik je kompleksniji za izračunavanje. Ukoliko je doneta odluka da se prekine antitrombotička terapija, sledeće pitanje je koliko pre operacije treba biti prekinuta i da li neophodno premošćavanje.
Reference
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
DefSemiHidden="false" DefQFormat="false" DefPriority="99"
LatentStyleCount="371">
UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
Name="index 1"/>
Name="index 2"/>
Name="index 3"/>
Name="index 4"/>
Name="index 5"/>
Name="index 6"/>
Name="index 7"/>
Name="index 8"/>
Name="index 9"/>
UnhideWhenUsed="true" Name="toc 1"/>
UnhideWhenUsed="true" Name="toc 2"/>
UnhideWhenUsed="true" Name="toc 3"/>
UnhideWhenUsed="true" Name="toc 4"/>
UnhideWhenUsed="true" Name="toc 5"/>
UnhideWhenUsed="true" Name="toc 6"/>
UnhideWhenUsed="true" Name="toc 7"/>
UnhideWhenUsed="true" Name="toc 8"/>
UnhideWhenUsed="true" Name="toc 9"/>
Name="Normal Indent"/>
Name="footnote text"/>
Name="annotation text"/>
Name="header"/>
Name="footer"/>
Name="index heading"/>
UnhideWhenUsed="true" QFormat="true" Name="caption"/>
Name="table of figures"/>
Name="envelope address"/>
Name="envelope return"/>
Name="footnote reference"/>
Name="annotation reference"/>
Name="line number"/>
Name="page number"/>
Name="endnote reference"/>
Name="endnote text"/>
Name="table of authorities"/>
Name="macro"/>
Name="toa heading"/>
Name="List"/>
Name="List Bullet"/>
Name="List Number"/>
Name="List 2"/>
Name="List 3"/>
Name="List 4"/>
Name="List 5"/>
Name="List Bullet 2"/>
Name="List Bullet 3"/>
Name="List Bullet 4"/>
Name="List Bullet 5"/>
Name="List Number 2"/>
Name="List Number 3"/>
Name="List Number 4"/>
Name="List Number 5"/>
Name="Closing"/>
Name="Signature"/>
UnhideWhenUsed="true" Name="Default Paragraph Font"/>
UnhideWhenUsed="true" Name="Body Text"/>
Name="Body Text Indent"/>
Name="List Continue"/>
Name="List Continue 2"/>
Name="List Continue 3"/>
Name="List Continue 4"/>
Name="List Continue 5"/>
Name="Message Header"/>
Name="Salutation"/>
Name="Date"/>
Name="Body Text First Indent"/>
Name="Body Text First Indent 2"/>
Name="Note Heading"/>
Name="Body Text 2"/>
Name="Body Text 3"/>
Name="Body Text Indent 2"/>
Name="Body Text Indent 3"/>
Name="Block Text"/>
Name="Hyperlink"/>
Name="FollowedHyperlink"/>
Name="Document Map"/>
Name="Plain Text"/>
Name="E-mail Signature"/>
Name="HTML Top of Form"/>
Name="HTML Bottom of Form"/>
Name="Normal (Web)"/>
Name="HTML Acronym"/>
Name="HTML Address"/>
Name="HTML Cite"/>
Name="HTML Code"/>
Name="HTML Definition"/>
Name="HTML Keyboard"/>
Name="HTML Preformatted"/>
Name="HTML Sample"/>
Name="HTML Typewriter"/>
Name="HTML Variable"/>
Name="Normal Table"/>
Name="annotation subject"/>
Name="No List"/>
Name="Outline List 1"/>
Name="Outline List 2"/>
Name="Outline List 3"/>
Name="Table Simple 1"/>
Name="Table Simple 2"/>
Name="Table Simple 3"/>
Name="Table Classic 1"/>
Name="Table Classic 2"/>
Name="Table Classic 3"/>
Name="Table Classic 4"/>
Name="Table Colorful 1"/>
Name="Table Colorful 2"/>
Name="Table Colorful 3"/>
Name="Table Columns 1"/>
Name="Table Columns 2"/>
Name="Table Columns 3"/>
Name="Table Columns 4"/>
Name="Table Columns 5"/>
Name="Table Grid 1"/>
Name="Table Grid 2"/>
Name="Table Grid 3"/>
Name="Table Grid 4"/>
Name="Table Grid 5"/>
Name="Table Grid 6"/>
Name="Table Grid 7"/>
Name="Table Grid 8"/>
Name="Table List 1"/>
Name="Table List 2"/>
Name="Table List 3"/>
Name="Table List 4"/>
Name="Table List 5"/>
Name="Table List 6"/>
Name="Table List 7"/>
Name="Table List 8"/>
Name="Table 3D effects 1"/>
Name="Table 3D effects 2"/>
Name="Table 3D effects 3"/>
Name="Table Contemporary"/>
Name="Table Elegant"/>
Name="Table Professional"/>
Name="Table Subtle 1"/>
Name="Table Subtle 2"/>
Name="Table Web 1"/>
Name="Table Web 2"/>
Name="Table Web 3"/>
Name="Balloon Text"/>
Name="Table Theme"/>
Name="List Paragraph"/>
Name="Intense Quote"/>
Name="Subtle Emphasis"/>
Name="Intense Emphasis"/>
Name="Subtle Reference"/>
Name="Intense Reference"/>
UnhideWhenUsed="true" Name="Bibliography"/>
UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
Name="Grid Table 1 Light Accent 1"/>
Name="Grid Table 6 Colorful Accent 1"/>
Name="Grid Table 7 Colorful Accent 1"/>
Name="Grid Table 1 Light Accent 2"/>
Name="Grid Table 6 Colorful Accent 2"/>
Name="Grid Table 7 Colorful Accent 2"/>
Name="Grid Table 1 Light Accent 3"/>
Name="Grid Table 6 Colorful Accent 3"/>
Name="Grid Table 7 Colorful Accent 3"/>
Name="Grid Table 1 Light Accent 4"/>
Name="Grid Table 6 Colorful Accent 4"/>
Name="Grid Table 7 Colorful Accent 4"/>
Name="Grid Table 1 Light Accent 5"/>
Name="Grid Table 6 Colorful Accent 5"/>
Name="Grid Table 7 Colorful Accent 5"/>
Name="Grid Table 1 Light Accent 6"/>
Name="Grid Table 6 Colorful Accent 6"/>
Name="Grid Table 7 Colorful Accent 6"/>
Name="List Table 1 Light Accent 1"/>
Name="List Table 6 Colorful Accent 1"/>
Name="List Table 7 Colorful Accent 1"/>
Name="List Table 1 Light Accent 2"/>
Name="List Table 6 Colorful Accent 2"/>
Name="List Table 7 Colorful Accent 2"/>
Name="List Table 1 Light Accent 3"/>
Name="List Table 6 Colorful Accent 3"/>
Name="List Table 7 Colorful Accent 3"/>
Name="List Table 1 Light Accent 4"/>
Name="List Table 6 Colorful Accent 4"/>
Name="List Table 7 Colorful Accent 4"/>
Name="List Table 1 Light Accent 5"/>
Name="List Table 6 Colorful Accent 5"/>
Name="List Table 7 Colorful Accent 5"/>
Name="List Table 1 Light Accent 6"/>
Name="List Table 6 Colorful Accent 6"/>
Name="List Table 7 Colorful Accent 6"/>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin-top:0in;
mso-para-margin-right:0in;
mso-para-margin-bottom:8.0pt;
mso-para-margin-left:0in;
line-height:107%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;}
Arepally B, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD et al. The use of antithrombotic ther-apies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Crit Pathw Cardiol 2010;9(1):41-48. [CrossRef] [PubMed]
Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl Med 2013;368(22):2113-24. [CrossRef] [PubMed]
Bhattad V, Gaddam S, Lassiter MA, Jagadish PS, Ardeshna D, Cave B et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med 2019;7(17):408. [CrossRef][PubMed]
Brilakis ES, Patel VG, Banerjee S. Medical manage-ment after coronary stent implantation: a review. J Am Med Assoc 2013;310:189-98. [CrossRef] [PubMed]
Capodanno D, Milluzzo RP, Angiolillo DJ. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention:from pharmacology to indications for clinical use. Ther Adv Cardiovasc Dis 2019;13: 1753944719893274. [CrossRef] [PubMed]
Chassot PG, Marcucci C, Delabays A, Spahn D. Peri-operative Antiplatelet Therapy. Am Fam Physician 2010;82(12):1484-89. [PubMed]
Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol 2016;68(24):2670-89. [CrossRef] [PubMed]
Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recur-rent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160(22):3431-6. [CrossRef] [PubMed]
Douketis JD, Spyropoulos AC, Duncan J, Carrier M , Le Gal G, Tafur AJ et al. Perioeprative Management of Patients With Atrial Fibrilation Receiving a Direct Oral Anticoagulant. JAMA Inten Med 2019;179(11):1469-78. [CrossRef] [PubMed]
Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH et al. Perioperative manage-ment of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2):e326s-e350s. [CrossRef] [PubMed]
Duminda N, Wijeysundera DN, Wijeysundera HC, Yun L, Wąsowicz M, Beattie WS et al. Risk of elective major noncardiac surgery after coronary stent in-sertion: a population-based study. Circulation 2012; 126(11):1355-62. [CrossRef] [PubMed]
Dunn AS, Spyropoulus A, Turpie AG. Bridging therapy in patients on long-term anticoagulants who require surgery: the prospective perioperative enoxaparin co-hort trial (PROSPECT). J Thromb Haemost 2007; 5(11):2211-8. [CrossRef] [PubMed]
Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and practice-based evidence in peri-procedural anticoagulation. Circulation 2012;126(13): 1573-6. [CrossRef] [PubMed]
Gažová A, Leddy JJ, Rexová M, Hlivák P, Hatala R, Kyselovič J. Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). Medicine (Baltimore) 2019;98(31):e16560. [CrossRef] [PubMed]
Hall R, Mazer CD. Antiplatelet drugs: A review of their pharmacology and management in perioperative pe-riod. Anesth Analg 2011;112(2):292-318. [CrossRef] [PubMed]
Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleve Clin J Med 2009;76(4):s37-44. [CrossRef] [PubMed]
Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336(21):1506. [CrossRef] [PubMed]
Kietaibl S, Ferrandis R, Godier A, Llau J, Lobo C, Macfarlane AJR et al. Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022;39:100-32. [CrossRef] [PubMed]
Kiran U, Makhija N. Patient with Recent Coronary Artery Stent Requiring Major Non Cardiac Surgery. Indian J Anaesth 2009;53(5):582-91. [PubMed]
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart sur-vey on atrial fibrilation. Chest 2010;137(2):263-72. [CrossRef] [PubMed]
Oprea AD, Popescu WM. Perioperative management of antiplatelet therapy. Br J Anaesth 2013;111(1):i3-i17. [CrossRef] [PubMed]
Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Blood 2012;120(24): 4699-705. [CrossRef] [PubMed]
Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl Med 2010;362(15): 1374-82. [CrossRef] [PubMed]
Plümer L, Seiffert M, Punke MA, Kersten JF, Blankenberg S, Zöllner C et al. Aspirin Before Elective Surgery-Stop or Continue? Dtsch Arztebl Int 2017; 114(27-28):473-80. [CrossRef] [PubMed]
Prendergast BD. Management of patients with pro-sthetic heart valves during non-cardiac surgery. Przegl Lek 2004;61:556-9.
Shah Z, Masoomi R, Tadors P. Managing antiplatelet therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. J Atr Fibrillation 2015;8(4):1318. [CrossRef] [PubMed]
Siegal D, Yudin J, Kaatz S, Doukites JD, Lim W, Spyropoulus AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thrombo-embolic rates. Circulation 2012;126(13):1630-9. [CrossRef] [PubMed]
Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate:an open-label, parallel-group single-centre study. Clin pharmacokinet 2010;49(4):259-68. [CrossRef] [PubMed]
Tafur A, Clark N, Spyropoulos A, Li N, Kaplovitch E, MacDougall K. Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. J Am Heart Assoc 2020;9:e017316. [CrossRef] [PubMed]
Thachil J. Antiplatelet therapy- a summary for the general physicians .Clin Med (Lond) 2016;16(2):152-160. [CrossRef] [PubMed]
Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures:risk and recomandations. Br J Haematol 2003;123(4):676-82. [CrossRef] [PubMed]
Watson RDS, Chin BSP, Lip GYH. Antithrombotic therapy in acute coronary syndromes. BMJ 2002; 325(7376):1348-51. [CrossRef] [PubMed]
Whitlock RP, Sun JC, Fremes SE, Robens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physi-cians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e576S-600S. [CrossRef] [PubMed]
Woods K, Douketis JD, Kathirgamanathan K, YI Q, Crowther MA. Low dose vitamin K to normalize the international normalized ratio prior to surgery in pa-tients who require temporary interruption of warfarin. J Thromb Thrombolysis 2007;24(2):93-7. [CrossRef] [PubMed]
Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED Score for Predicting Major bleeding risk in anticoagu-lated patients with atrial fibrillation: A systemic review and meta-analysis. Clin Cardiol 2015;38(9):555-61. [CrossRef] [PubMed]
Zwart B, Godschalk TC, Kelder JC, Ten Berg JM. High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS. J Interv Cardiol 2017;30(5):421-6. [CrossRef] [PubMed]